Diagnostic Performance of Plasma p-Tau Biomarkers Across Alzheimer's Disease Continuum

18 high-quality studies comprising 24 independent datasets and 4,736 participants were included in this network meta-analysis. The research, authored by Xiaofen Chen and uploaded to figshare in June 2026, systematically compares the diagnostic accuracy of plasma p-tau217, p-tau181, and p-tau231 isoforms. It finds plasma p-tau217 measured by mass spectrometry offers the highest accuracy for detecting amyloid-β pathology and predicting cognitive decline.

Use Cases

• Benchmarking diagnostic performance of blood-based biomarkers based on reported Area Under the Curve (AUC) metrics.
• Comparing analytical platforms (mass spectrometry vs. immunoassay) for phosphorylated tau isoforms mentioned in the description.
• Training models for disease staging and predicting MCI-to-dementia conversion based on p-tau marker performance.
• Evaluating the incremental value of biomarker ratios (e.g., p-tau217/Aβ42) for patient stratification.

Strengths

• Includes data from 4,736 participants across rigorously screened, independent cohorts.
• Provides direct comparisons of diagnostic accuracy (P-scores) for multiple p-tau isoforms and platforms.
• Conducts subgroup analyses confirming performance across Han Chinese and Western cohorts.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale model training.
• The dataset is small (11.2 KB), indicating limited scope, likely containing summary statistics rather than raw participant-level data.

Provenance

Source

Network meta-analysis of published studies, uploaded to figshare.

Collection Method

Systematic review and meta-analysis of studies reporting diagnostic accuracy of plasma p-tau biomarkers.

Freshness

Last updated 2026-06-03 06:45:16; freshness should be verified.

Geography

Includes data from Han Chinese and Western cohorts.